Difference between revisions of "Category:Bcr-Abl inhibitors"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
Drugs that inhibit Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome 9:22 translocation seen in [[Chronic myelogenous leukemia|chronic myelogenous leukemia (CML)]] and some [[Acute lymphocytic leukemia|acute lymphocytic leukemias (ALL)]]. | Drugs that inhibit Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome 9:22 translocation seen in [[Chronic myelogenous leukemia|chronic myelogenous leukemia (CML)]] and some [[Acute lymphocytic leukemia|acute lymphocytic leukemias (ALL)]]. | ||
| − | [[Category: | + | [[Category:Tyrosine kinase inhibitors]] |
Latest revision as of 21:55, 22 January 2021
Drugs that inhibit Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome 9:22 translocation seen in chronic myelogenous leukemia (CML) and some acute lymphocytic leukemias (ALL).
Pages in category "Bcr-Abl inhibitors"
The following 8 pages are in this category, out of 8 total.